Modeling EBV infection and pathogenesis in new-generation humanized mice.
- Author:
Shigeyoshi FUJIWARA
1
;
Ken Ichi IMADOME
;
Masami TAKEI
Author Information
- Publication Type:Research Support, Non-U.S. Gov't ; Review
- MeSH: Animals; Disease Models, Animal; Epstein-Barr Virus Infections/complications/immunology/*virology; Herpesvirus 4, Human/*physiology; Heterografts; Humans; Killer Cells, Natural/pathology/virology; Lymphoproliferative Disorders/etiology; Mice; Mice, SCID; T-Lymphocytes/pathology/virology
- From:Experimental & Molecular Medicine 2015;47(1):e135-
- CountryRepublic of Korea
- Language:English
- Abstract: The development of highly immunodeficient mouse strains has allowed the reconstitution of functional human immune system components in mice. New-generation humanized mice generated in this manner have been extensively used for modeling viral infections that are exclusively human tropic. Epstein-Barr virus (EBV)-infected humanized mice reproduce cardinal features of EBV-associated B-cell lymphoproliferative disease and EBV-associated hemophagocytic lymphohistiocytosis (HLH). Erosive arthritis morphologically resembling rheumatoid arthritis (RA) has also been recapitulated in these mice. Low-dose EBV infection of humanized mice results in asymptomatic, persistent infection. Innate immune responses involving natural killer cells, EBV-specific adaptive T-cell responses restricted by human major histocompatibility and EBV-specific antibody responses are also elicited in humanized mice. EBV-associated T-/natural killer cell lymphoproliferative disease, by contrast, can be reproduced in a distinct mouse xenograft model. In this review, recent findings on the recapitulation of human EBV infection and pathogenesis in these mouse models, as well as their application to preclinical studies of experimental anti-EBV therapies, are described.
